Welcome to PhalanxNeuro

PhalanxNeuro will bring precision medicine for neurodegenerations within reach. Solutions for the early and accurate identification of different diseases are in great need. We will facilitate the development of patient-specific medicines, and the early assignment of personalized treatments.

PhalanxNeuro is a Prosperodes brand.

Neurodegenerations

Neurodegenerations have long become widespread in our increasingly aging society. The most common diseases include Alzheimer's disease, Parkinson's disease, Lewy body dementia, fronto-temporal dementia and amyotrophic lateral sclerosis.

The progressive aggregation of proteins in the form of amyloid-like deposits by a "seeding" mechanism is very common in these diseases.

Landmark research recently demonstrated that even the most studied neurodegeneration – Alzheimer's disease – is constituted of a range of disease subtypes⁽¹⁾. This substantially adds to the complexities that have to be addressed from early drug discovery to clinical application.

⁽¹⁾ Vogel, J.W., Young, A.L., Oxtoby, N.P. et al. Nat Med 27, 871–881 (2021).

Approach

Our proprietary technology mimics the "seeding" mechanism of protein aggregation by an in vitro process. The detection of multiple "seed"-biomarker proteins allows to determine seeding activity, seed-subtypes and co-pathologies.

Our product philosophy include versatility for a wide range of biomarkers, process accuracy and integration, and robust IVD certifiability.

Team